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Abstract
Glycosylation is the most complex post-translational modification of proteins. Altered glycans on the tumor- and
host-cell surface and in the tumor microenvironment have been identified to mediate critical events in cancer
pathogenesis and progression. Tumor-associated glycan changes comprise increased branching of N-glycans,
higher density of O-glycans, generation of truncated versions of normal counterparts, and generation of unusual
forms of terminal structures arising from sialylation and fucosylation. The functional role of tumor-associated
glycans (Tn, sTn, T, and sLea/x) is dependent on the interaction with lectins. Lectins are expressed on the surface of
immune cells and endothelial cells or exist as extracellular matrix proteins and soluble adhesion molecules.
Expression of tumor-associated glycans is involved in the dysregulation of glycogenes, which mainly comprise
glycosyltransferases and glycosidases. Furthermore, genetic and epigenetic mechanisms on many glycogenes are
associated with malignant transformation. With better understanding of all aspects of cancer-cell glycomics, many
tumor-associated glycans have been utilized for diagnostic, prognostic, and therapeutic purposes. Glycan-based
therapeutics has been applied to cancers from breast, lung, gastrointestinal system, melanomas, and lymphomas
but rarely to neuroblastomas (NBs). The success of anti-disialoganglioside (GD2, a glycolipid antigen) antibodies
sheds light on glycan-based therapies for NB and also suggests the possibility of protein glycosylation-based
therapies for NB. This review summarizes our understanding of cancer glycobiology with a focus of how protein
glycosylation and associated glycosyltransferases affect cellular behaviors and treatment outcome of various
cancers, especially NB. Finally, we highlight potential applications of glycosylation in drug and cancer vaccine
development for NB.
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Background
Glycosylation is the most complex post-translational
modification of proteins and is involved in many
physiological events, such as host-pathogen interaction,
cell differentiation and trafficking, and intracellular and
intercellular signaling. Tumor-associated glycan changes
comprise increased branching of N-glycans, higher density
of O-glycans, generation of truncated versions of normal
counterparts (Tn, sTn, and T antigens), and generation of
unusual forms of terminal structures with sialic acid and
fucose (sLea and sLex epitopes), mainly caused by the
genetic and epigenetic desregulation of glycogenes and the
tumor microenvironment. Changes in oligosaccharide
structures of glycoproteins or glycolipids are involved in
cancer progression through the dysregulation of cell cycle,
promotion of cell proliferation and growth, degradation of
the extracellular matrix (ECM) and basement membranes,
promotion of tumor dissemination and angiogenesis, and
facilitation of immune evasion [1]. A massive potential for
glycan diversity exists; however, a limited range of glycans
are associated with invasion and metastatic potential in
various tumors [1]. The endogenous animal lectins
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(glycan-binding proteins) participate in fundamental
processes such as quality control of secreted proteins,
host-pathogen recognition, cell adhesion, and motility.
The interactions of lectins with tumor-associated glycans
facilitate tumor progression in lung cancers, colon
cancers, pancreatic carcinomas, melanomas, and neuro-
blastomas (NBs) [2–6].
NB is the most common extracranial solid tumor in
children and the most common solid tumor of infancy,
accounting for about 8–10 % of childhood cancers and for
about 15 % of cancer deaths in children. The median age of
children at diagnosis is 22 months, and 90 % of cases are
diagnosed by 5 years of age. The annual incidence is esti-
mated to be about 1/70,000 in children under the age of 15
[7]. There are ~150 new cases diagnosed each year in Japan
and 30~40 new cases diagnosed each year in Taiwan
according to the Japan Neuroblastoma Study Group and
the Registry of Childhood Cancer Foundation of Taiwan,
respectively [8, 9]. NB is a genetically and clinically hetero-
geneous cancer arising from embryonal sympathetic ner-
vous system, exhibiting from spontaneous differentiation or
regression with a favorable prognosis to highly undifferenti-
ated tumors with rapid progression and very poor
outcomes [7]. Although the overall prognosis of NB
patients has improved remarkably with recent therapeutic
advances, long-term survival of aggressive forms of NB
remains poor even with intensive multimodal therapy [7].
The Children’s Oncology Group stratified patients into
low-, intermediate-, or high-risk groups based on age at
diagnosis, International Neuroblastoma Staging System
(INSS) stage [10], tumor histology, DNA index (ploidy),
and MYCN (V-myc myelocytomatosis viral-related
oncogene) amplification status [11]. The osteomedullary
recurrences from residual disease often result in treatment
failure; in addition, the NB patients in either intermediate-
or high-risk group present with prognostic heterogeneity. It
is therefore important to identify more useful cancer
biomarkers which allow for subgrouping NB patients as
homogeneously as possible in terms of biology and out-
come. Glycan-based therapeutics has been applied to can-
cers from breast, lung, gastrointestinal system, melanomas,
and lymphomas but rarely to NBs [12–19]. In NB, disialo-
ganglioside (GD2; a surface glycolipid synthesized by GD2
synthase) is uniformly expressed by virtually all neuroblasts
and facilitates the attachment of NB cells to ECM [20]. This
feature makes GD2 a potential molecular marker for
residual disease detection and a target for immunotherapy.
The success of anti-GD2 antibodies suggests that glycan-
based therapies may be effective in patients with high-risk
NB. Researchers have also envisaged the possibility of using
protein glycosylation-based therapies to treat NB.
This review summarizes our understanding of cancer
glycobiology and focuses on how protein glycosylation
affects the cellular behavior and treatment outcomes of
various cancers, especially NB. The effects exerted by
glycosyltransferases, tumor cell-cell, and tumor cell-
ECM interactions are also elucidated. Finally, this review
discusses the advances in glycan-based therapies that
have been utilized for a variety of cancers, such as gly-
cosyltransferase inhibitors, glycomimetics, and glycan-
based vaccines/immunotherapies. It is anticipated that
NB-associated glycoforms regulated by genetic and
epigenetic machinery will provide information with
which novel therapeutic targets can be identified, and
new therapies can be developed.
Protein glycosylation in normal and malignant
cells
N- and O-glycosylation of proteins
Glycans are expressed in several types of glycoconjugates,
namely glycoproteins, glycosphingolipids, proteoglycans/gly-
cosaminoglycans (GAGs), and glycosylphosphatidylinositol
(GPI)-linked proteins. During protein synthesis, glycans
assure correct folding in the endoplasmic reticulum (ER)
and are involved in trafficking of newly synthesized proteins
[21]. They also protect proteins from degradation inside or
outside the cell by means of interfering with proteolysis.
Many glycans act as receptors for bacteria, viruses, and
other pathogens. The cell-surface sugar structures allow the
immune cells to differentiate self/normal cells from non-
self/abnormal cells. They are also involved in cell-cell and
cell-matrix interactions which are associated with cancer-
cell invasion to the surrounding tissue or extravasation to
form metastatic lesions [22].
There are two major types of protein glycosylation in
mammalian cells, namely N-linked and O-linked. Both
types often coexist in the same protein. The synthesis of
N-glycans is initiated in the ER by transfer of a
preformed lipid (dolichopyrophosphate)-linked oligosac-
charide precursor containing three glucoses, nine
mannoses, and two N-acetylglucosamines, written as
(Glc)3(Man)9(GlcNAc)2, to asparagine of nascent
proteins. Subsequent processing occurs in the ER for
protein folding, including cycles of glucose removal and
addition. N-glycan chains can be further diversified in
the Golgi apparatus as well [23]. N-glycans can be
divided into three types according to the sugar moiety
structures: high-mannose type, hybrid type, and complex
type (Fig. 1). O-glycans are synthesized in the ER, Golgi
apparatus, or cytosol by stepwise enzyme transfer of
monosaccharides without the need of dolichol carrier.
The frequency of O-glycosylation on many glycoproteins
is high, especially on secreted or membrane-bound
mucins, which are rich in serine and threonine. Mucin-
type O-glycosylation which is the most common type of
O-glycosylation in mammals is highly conserved in the
evolutional course of many species; it is initiated by the
transfer of N-acetylgalactosamine (GalNAc) to a serine
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or threonine residue, thereby forming the Thomsen-
nouvelle antigen (Tn Ag) (Fig. 2) [24]. This reaction is
catalyzed by a family of polypeptide GalNAc transferases
(GALNTs) that consists of at least 20 members in
humans, namely GALNT1 to 20 [25]. T synthase (or
core 1 β1,3-galactosyltransferase (C1GALT1)) galactosy-
lates Tn to form the core 1 (Galβ1→ 3GalNAc, T
antigen) [26]. Core 2 is formed by adding a branching
GlcNAc to core 1 by core 2 β1,6-N-acetylglucosaminyl-
transferases (GCNTs 1, 3, and 4) [27]. Alternatively to
the core 1 structure formation, GlcNAc instead of Gal
can be transferred in a β1–3 linkage forming the core 3
structure by β1,3-N-acetylglucosaminyltransferase 6
(B3GNT6) [28]. Core 3 may serve as an acceptor
substrate for the core 4 enzyme, GCNT3, which adds
GlcNAc in a β1-6 linkage to GalNAc (Fig. 2). Core
structures 5–8 have an extremely restricted occurrence,
and core 7 has not been found in humans [29]. Other
non-mucin-type O-glycosylations are not further
discussed in this review.
Lectins (glycan-binding proteins)
Three main types of lectins, namely siglecs, galectins, and
selectins, are glycan-binding proteins (GBPs) that are highly
specific for sugar moieties. In healthy organisms, various
endogenous lectins are associated with fundamental
processes such as cell-cell recognition, cell adhesion and
motility, and pathogen-host recognition. Many lectins are
expressed on the surface of immune cells and endothelial
cells or exist as ECM proteins and soluble adhesion mole-
cules [1]. Siglecs are sialic acid-binding immunoglobulin-
like lectins, which are expressed on specific subpopulations
of hematopoietic cells such as macrophages, natural killer
cells, and B cells. The binding of siglecs to tumor-derived
glycans may exert various immune activities leading to
anti-tumor immunity or tumor escape of immune
surveillance [5]. The galectin family consists of 15
members, which are expressed by various cell types includ-
ing epithelial and immune cells. Galectins belong to soluble
(different from the membrane-bound nature for siglecs and
selectins) immunomodulatory lectins and bind to galactose
Fig. 1 An overview of the process of N-glycosylation. Glycosyltransferases involved in the synthesis are indicated. Additional modifications exist
(not shown). Dol dolichopyrophosphate, MGAT β1,6-N-acetylglucosaminyltransferase, MANII mannosidase II, GlcNAc N-acetylglucosamine, Man
mannose, Gal galactose, NeuAc N-acetylneuraminic acid, Fuc fucose. Glycosyltransferases shown in Table 1 are highlighted, except B4GALNT3
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that is either β1,3 or β1,4-linked to N-acetylglucosamine at
the cell surface, forming lattices that fine-tune the dynamics
of receptor-ligand interactions. Accumulating evidence
indicates that cancer-associated galectins facilitate invasive
phenotype of tumor cells [30]. The selectin family consists
of L-, E-, and P-selectin, which share ~50 % sequence
homology in the C-type lectin domain. Their ligands typic-
ally consist of glycans capped with sialic acid, fucose, and
sulfate. Selectins normally mediate adhesion of platelets
(which express P-selectins), homing and development of
leukocytes/lymphocytes (which express L-selectins), and
recruitment of immune cells in response to inflammation
(E- and P-selectins). The interactions between lectins and
tumor cell-derived glycans alter tumor cell-cell interaction
and cell-ECM adhesion, thereby facilitating tumor progres-
sion/dissemination [1].
Altered protein glycosylation in cancers
Altered glycosylation of membrane-bound (such as cyto-
kine or growth factor receptors, integrins, and cadherins)
and secreted glycoproteins is associated with various can-
cers [31, 32]. Ogata et al. found that malignant cells are
more enriched in highly branched complex-type N-linked
sugar chains than their normal counterparts [33]. Many
subsequent studies confirmed that an increase of β1–6
branching of the complex-type N-linked sugar chains is
associated with cancer growth and metastasis. β1,6-N-
acetylglucosaminyltransferase V (GnT-V; MGAT5) is one
of the most relevant glycosyltransferases associated with
cancer migration, invasion, and metastasis (Fig. 3). This
enzyme is responsible for adding GlcNAc in a β1,6-link-
age, initiating the fourth branch in a sequential pathway to
tetraantennary N-glycans (Figs. 1 and 3) [34]. In human
breast and colorectal cancers, the expression of β1–6
branched oligosaccharides regulated by GnT-V can serve
as a marker for tumor progression, metastasis, and poor
prognosis [35, 36]. However, GnT-V may exhibit opposite
effects on other neoplasms. For example, GnT-V expres-
sion predicts a favorable prognosis and treatment
outcome in lung cancers and NB [37, 38]. On the other
hand, GnT-III catalyzes the attachment of a GlcNAc to a
core mannose of N-glycan via a β1,4-linkage to form the
bisecting GlcNAc structure and has been proposed to
antagonize GnT-V, thereby contributing to the suppres-
sion of cancer metastasis [39].
Many mucin-type O-glycosyltransferases have been
assigned biological functions, and aberrant expression of
these enzymes is associated with human diseases. For ex-
ample, the expression of N-acetylgalactosaminyltransferase
(GALNT) 3 is a potential diagnostic and prognostic marker
for lung [40] and pancreatic [41] cancers. GALNT6 can
glycosylate and stabilize oncoprotein mucin 1 (MUC1),
thereby contributing to mammary carcinogenesis via
disruption of cell adhesion molecules (β-catenin and E-cad-
herin). The same research team also found that GALNT6-
fibronectin pathway is also a critical component for breast
Fig. 2 Biosynthetic pathways of mucin-type O-glycans. Glycosyltransferases involved in the synthesis are indicated. Additional modifications exist
(not shown). B3GALT5 β1,3-galactosyltransferase 5, B3GNT β1,3-N-acetylglucosaminyltransferase; B4GALTs, β1,4-galactosyltransferases, C1GALT1, core
1 β1,3-galactosyltransferase, Fuc-T fucosyltransferase, GCNT β1,6-N-acetylglucosaminyltransferase, ST3Gal Gal: α2,3-sialyltransferase, ST6Gal-I Gal:
α2,6-sialyltransferase-I, ST6GalNAc GalNAc: α2,6-sialyltransferase, ST6GlcNAc-I GlcNAc: α2,6-sialyltransferase-I, ppGALNTs UDPGalNAc-polypeptide
N-acetylgalactosaminyltransferases, GalNAc N-acetylgalactosamine, GlcNAc N-acetylglucosamine, Gal galactose, NeuAc N-acetylneuraminic acid,
Fuc fucose. Glycosyltransferases shown in Table 1 are highlighted, except B4GALNT3
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cancer development and progression [42, 43]. GALNT14
modulates death-receptor O-glycosylation in pancreatic
carcinoma, non-small-cell lung carcinoma, and melanoma
cells, and may therefore serve as a predictive biomarker for
Apo2L/tumor necrosis factor-related apoptosis-inducing
ligand-based cancer therapy [44].
Increased expression of shorter O-glycan structures such
as Thomsen-Friedenreich (T), Tn, sialyl-Tn (sTn), and
common tumor-cell epitopes such as sialyl-Lewis A (sLea)
and sialyl-Lewis X (sLex) has been observed in a number of
carcinomas of several organs (such lung, colon, stomach,
and pancreas) and is associated with malignant trans-
formation, cancer growth, and metastatic ability [45–49].
Impaired function of glycosyltransferases responsible for
the synthesis of core structures used as substrates of chain
elongation and/or overexpression of sialyltransferases (such
as sialyltransferases ST6GalNAc-I and ST3Gal-I) respon-
sible for the synthesis of sTn and sT antigens may result in
increased expression of incomplete glycan structures
(Fig. 2) [50, 51]. The chaperone protein Cosmc is respon-
sible for folding and stability of β1,3-galactosyltransferase
(T synthase). Mutation in Cosmc chaperone leads to
increased Tn and sTn expression in colon carcinoma and
melanoma cells [52]. Mucins contain both O-linked and
N-linked oligosaccharides and are major carriers of these
cancer-associated carbohydrates. Multiple mucin domains
differentially interact and regulate different components of
the tumor microenvironment [53].
Altered lectin-glycan interactions in cancers
The functional role of tumor-associated glycans has been
noted to be dependent on lectin binding. Miyazaki et al.
reported that non-malignant colon epithelial cells
express di-sLea and 6-sulfo sLex which serve as ligands
for siglec-7 and siglec-9 on resident macrophages in the
colonic lamina propriae. Expression of di-sLea and
Fig. 3 Altered glycans and related pathophysiological events involved in NB progression. a β1,4-N-acetylgalactosaminyltransferase 3 (B4GALNT3)
and β1,4-galactosyltransferase 3 (B4GALT3) exhibit differential effects on malignant phenotypes by modification of β1 integrin in NB cells; b
N-acetylgalactosaminyltransferase 2 (GALNT2) modifies O-glycans on IGF-1R, thereby suppressing IGF-1-induced IGF-1R dimerization and
downstream signaling; c N-acetylglucosaminyltransferase V (GnT-V) modulates the sensitivity of NB to apoptosis; d Gal-1 promotes attachment of
NB cells to the extracellular matrix (ECM) and endothelial cells through binding to CD44. Besides, Gal-1 may dampen the function of T cells and
dendritic cells as well. Glycosaminoglycans present as e free polysaccharides (hyaluronic acid), a major counterreceptor for f CD44, or g as part of
proteoglycans (heparan sulfate and chondroitin sulfate). GalNAc N-acetylgalactosamine, GlcNAc N-acetylglucosamine, Gal galactose, NeuAc,
N-acetylneuraminic acid, Fuc fucose, Glc glucose, Man mannose, Xyl xylose, GlcA glucuronic acid, IdoA iduronic acid
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6-sulfo sLex was decreased during malignant transform-
ation, and was replaced by increased expression of sLea
and sLex which have no siglec ligand activity.
Meanwhile, they found that normal glycans of epithelial
cells exert a suppressive effect on cyclooxygenase-2
expression by resident macrophages, thus maintaining
immunological homeostasis in colonic mucosal
membranes, whereas loss of immunosuppressive glycans
by impaired glycosylation during colonic carcinogenesis
enhances inflammatory damage of the colonic mucosa
[5]. Galectins, another type of lectins, are versatile mod-
ulators of cancer growth and metastasis. Tumor-derived
galectin-1 (Gal-1) induces tumor angiogenesis and
promotion of immunosuppression by T cell apoptosis in
several types of cancers, including melanomas, NB, lung
cancers, and pancreatic carcinomas, therefore correlat-
ing with tumor aggressiveness and metastasis [3, 4].
Expression of the α2,6-sialyltransferase-1 (ST6Gal-I)
specifically resulted in increased sialylation of N-glycans
on CD45, a receptor tyrosine phosphatase of T cell
receptor for Gal-1, thereby inhibiting Gal-1 binding
activity and Gal-1-induced T cell death [54]. In addition,
Gal-1 might also be involved in alteration of tumor cell--
cell and cell-matrix interactions and formation of
platelet-cancercell complexes [1]. N-glycans are the
major ligands for galectin-3 at the cell surface [55].
Oncogenesis increases lectin-glycoprotein lattice by up-
regulating galectin-3 gene expression and higher-affinity
N-glycan ligands, which in turn enhances the availability
of tyrosine kinase receptors for epidermal growth factor
(EGF), transforming growth factor (TGF)-β, insulin-like
growth factor (IGF) and platelet-derived growth factor
(PDGF) in a ligand-sensitive state [56]. For all three
selectins, the minimal recognition epitopes are sLex/a
(Fig. 2) which are present on blood cells, certain vascular
endothelial cells, and glycoconjugates of the tumor-cell
surface. The most common mucins carrying selectin
ligands that are associated with cancer dissemination are
MUC1, MUC2, MUC4, and MUC16 [57–59]. Besides,
other selectin ligands carriers on tumor cells include
P-selectin glycoprotein ligand-1, CD24, CD44 (which
carries T and sTn antigens) (Fig. 3) [60], death-receptor 3,
E-selectin glycoprotein ligand-1 [61]. Selectin-mediated
interactions facilitate metastatic seeding by increased
vascular permeability, forming aggregates with platelets
and leukocytes, and lodgment in the small vessels of
distant organs [62].
The impacts of altered protein glycosylation on
NB
Altered N- and O-glycans in NB
N-linked glycosylation is a highly regulated post-
translational modification, which is associated with many
biological processes. It was found that the expression of
intercellular adhesion molecule-2 (ICAM-2) suppresses
tumor dissemination in a murine model of metastatic
NB. Reduced N-glycosylated ICAM-2 by site-directed
mutagenesis resulted in an attenuated ability to suppress
metastasis of NB cells [63, 64]. Anaplastic lymphoma
kinase (ALK) protein expression is up-regulated signifi-
cantly in advanced/metastatic NB compared with local-
ized NB, regardless the presence of mutated or wild-type
ALK [65, 66]. Inhibition of N-linked glycosylation by
tunicamycin affects ALK phosphorylation and disrupts
downstream pro-survival signaling in vitro, indicating
that inhibition of this post-translational modification
may be a promising therapeutic approach [67]. However,
as tunicamycin is not a likely candidate for clinical use,
future studies will assess whether the efficacy in inhibit-
ing ALK activity might be enhanced by the combination
of ALK specific small molecules [68, 69] and N-linked
glycosylation inhibitors.
While altered protein glycosylation is a hallmark of car-
cinomas, which express truncated O-glycans or sialylated
versions of the normal counterparts at the cell surface (such
as Tn, T, and sTn antigens), evidence suggests that mucin-
type O-glycosyltransferases play an important role in NB
biology, which is discussed further in the next section.
The role of glycosyltransferases in NB
Because aberrant expression of N-glycans and short O-gly-
cans has been detected in human NB cells, and their
expression levels are regulated by associated glycosyltrans-
ferases [70], many research groups have been looking for
potential glycosyltransferases as markers for residual dis-
ease detection, risk group assignment, and the prognostic
factor. The authors found that GnT-V expression predicted
a favorable prognosis and treatment outcome in NB.
Additionally, GnT-V knockdown in NB cells resulted in a
decrease in retinoic acid-induced apoptosis accompanied
by morphological changes [38]. Using oligomicroarray
transcriptome analysis between primary tumor versus bone
marrow metastatic cell lines, Berois et al. reported that
GALNT13 may serve as an informative marker for the
molecular diagnosis of bone marrow involvement and the
follow-up of minimal residual disease (MRD) in NB
patients [71]. By contrast, GALNT9 was expressed in
neuroblasts derived from the primary tumor in the IGR-N-
91 NB model [72] but not in those derived from metastatic
bone marrow and may serve as a prognostic marker for
better clinical outcome in NB patients [73]. Over the past
few years, our team had studied a series of glycosyltransfer-
ases which were reported to have prognostic impacts on
NB in the public microarray datasets of Oncogenomics
(https://pob.abcc.ncifcrf.gov/cgi-bin/JK). The expression
status, clinical relevance, and functional role of these glyco-
syltransferases in NB as well as other cancers are discussed
as follows.
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β1,3-N-acetylglucosaminyltransferase 3
β1,3-N-acetylglucosaminyltransferase 3 (B3GNT3) is re-
sponsible for adding GlcNAc to core 1 (T antigen: T Ag)
in a β1,3-linkage, forming extended core 1 oligosaccha-
rides (Fig. 2). B3GNT3 belongs to the β3GlcNAcT gene
family, which consists of at least eight different
β3GlcNAcTs [74]. B3GNT3 was identified for the first
time to express in the high endothelial venules (HEVs)
of secondary lymphoid organs; it contributes to the
synthesis of HEV-borne L-selectin ligands and the
lymphocyte homing [75]. B3GNT3 is also expressed in
lymphocytes and neutrophils, involving in the biosyn-
thesis of the backbone structure of sLex/a, which plays a
critical role in E-selectin adhesion [75, 76]. Genetic
variation in B3GNT3 gene was correlated with the risk
of non-Hodgkin lymphoma [76] and the CA19-9 plasma
concentration (e.g., detection of sLea epitope) [77].
However, our research team demonstrated that B3GNT3
expression examined using immunohistochemistry
(IHC) correlates positively with the histological grade of
differentiation as well as favorable Shimada histology
and is an independent prognostic factor of better
survival outcome for NB. Cell line experiments
demonstrated that B3GNT3 expression decreases core 1
(T antigen) as well as malignant phenotypes including
migration and invasion (Table 1) [78].
β1,4-N-acetylgalactosaminyltransferase 3
β1,4-N-acetylgalactosaminyltransferase 3 (B4GALNT3)
has been cloned, and its transcript is highly expressed in
stomach, colon, and testis [79]. This enzyme can transfer
GalNAc to any nonreducing terminal GlcNAc-β in vitro,
resulting in the synthesis of GalNAcβ1,4GlcNAc
(LacdiNAc or LDN). This special terminal β1,4GalNAc
structure is found in certain glycoproteins and glycohor-
mones; one of them is the sorting protein-related recep-
tor SorLA/LR11 which shuttles between the plasma
membrane, endosomes, and the Golgi. SorLA/LR11,
highly expressed by neurons in the central and periph-
eral nervous systems, bears N-linked oligosaccharides
modified with terminal β1,4-linked GalNAc-4-SO4 that
can be synthesized by B4GALNT3 in CHO cells [80]. By
using IHC analysis to examine the B4GALNT3 expres-
sion in NB tumors, we found that B4GALNT3 expres-
sion correlates positively with the differentiation status
of NB and early clinical stage (INSS stage 1, 2, and 4S)
and may predict a favorable prognosis independently.
Cell line experiments demonstrated that B4GALNT3
suppresses NB cell proliferation, migration, and invasion
primarily by increasing LacdiNAc modification of β1
integrin, thereby inhibiting the downstream signaling of
β1 integrin (Table 1) [81]. However, in human colon
cancers, our research team previously presented that
Table 1 Glycosyltransferases as prognostic markers with differential effects on neuroblastoma and other cancers
Enzymes Glycosylation
involved
Target proteins and associated signaling pathways Clinical significance
β1,3-N-acetylglucosaminyltransferase
3 (B3GNT3)
O-glycosylation B3GNT3 inhibits NB cell migration and invasion by







B4GALNT3 inhibits NB cell migration and invasion by
modifying β1 integrin with LacdiNAc, thereby suppresses
the activation of Akt and ERK signaling pathways.
B4GALNT3 enhances the stemness, migration, and invasion
by modifying primarily N-glycans with LacdiNAc on EGFR









B4GALT3 increases NB cell migration and invasion by
modifying lactosamine structures of β1 integrin, delaying
the degradation of β1 integrin, and enhancing its
downstream signaling.
B4GALT3 suppresses CRC cell migration and invasion by
inhibiting β1 integrin activation through altering the








O-glycosylation GALNT2 regulates NB cell growth, migration, and invasion
by modifying O-glycans on IGF-1R, thereby suppressing
IGF-1-induced IGF-1R dimerization and downstream signaling.
GALNT2 inhibites HCC cell proliferation, migration, and
invasion by modifying O-glycans on EGFR, thereby suppressing
EGF-induced endocytosis of EGFR and downstream signaling.
GALNT2 enhances OSCC cell migration and invasion by









N-glycosylation GnT-V knockdown results in a decrease in the susceptibility
to cell apoptosis induced by retinoic acid in NB cells
accompanied by morphological change
Predicts good prognosis
in NB [38].
FAK focal adhesion kinase, ERK extracellular signal kinase, LacdiNAc the structure of GalNAcβ1,4GlcNAc
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B4GALNT3 messenger RNA (mRNA) is frequently up--
regulated in primary colon cancer tumors compared
with their normal counterparts. B4GALNT3 overexpres-
sion significantly promotes malignant behaviors of colon
cancer cells both in vitro and in vivo through enhanced
mitogen-activated protein kinase (MAPK) signaling
pathways [82]. We later found that B4GALNT3 expres-
sion examined using IHC staining correlates positively
with advanced American Joint Committee on Cancer
stages, high metastasis rates, and poor survival in colo-
rectal cancer patients. Moreover, cell line experiments
revealed that B4GALNT3 expression regulates cancer
stemness and the invasive properties of colon cancer
cells through modifying epidermal growth factor recep-
tor (EGFR) glycosylation and downstream signaling
(Table 1) [83].
β1,4-galactosyltransferase 3
Another interesting glycosyltransferase, β1,4-galactosyl-
transferase 3 (B4GALT3), is a member of the B4GALT
family composed of seven isoenzymes and is responsible
for transferring galactose from UDP-Gal to GlcNAc-
terminated oligosaccharides on N-glycans, O-glycans,
glycolipids, or GAG chains to form poly-N-acetyllactosa-
mines (Fig. 2) [84]. B4GALT3 has been noted to have
higher expression levels in fetal brains than in adult
brains [85]. Our research team found that positive
B4GALT3 expression examined by IHC staining in NB
tumor tissues correlates negatively with the histological
grade of differentiation and early clinical stage and is an
unfavorable prognostic factor independent of other
factors for NB patients. Moreover, B4GALT3 increases
poly-N-acetyllactosamine levels on the mature form of
β1-integrin, which delays β1-integrin degradation and
enhances its downstream signaling, thereby increasing
NB cell migration and invasion (Table 1) [86]. Our team
later reported that the expression level of B4GALT3 in
colorectal cancer (CRC) patients negatively correlates
with poorly differentiated histology, advanced stages,
and metastasis. Cell line experiments revealed that
B4GALT3 overexpression inhibits CRC cell malignant
phenotypes by decreasing the synthesis of poly-N-acetyl-
lactosamines on N-glycans of β1-integrin, which in turn
suppresses its downstream signaling related to cell
attachment to ECM, cell migration, and invasion
(Table 1) [87].
N-acetylgalactosaminyltransferase 2
N-acetylgalactosaminyltransferase 2 (GALNT2), a mem-
ber of the GALNT family responsible for initiation of
mucin-type O-glycosylation (Fig. 2), has been found to
express differentially in nervous tissues during mouse
embryogenesis [88]. The expression of GALNT2 also
regulates migration and invasion of human glioma cells
in vitro [89]. In NB, we found that increased GALNT2
expression examined using IHC in primary tumor
tissues correlates well with the histological grade of
differentiation and early clinical stage and may serve as
an independent prognostic factor for better survival of
NB patients. In vitro and in vivo experiments using over-
expression and knockdown revealed that the expression
of GALNT2 suppresses IGF-1-induced cell growth, mi-
gration, and invasion of NB cells by modifying O-glycans
on IGF-1R, which suppresses IGF-1-triggered IGF-1R
dimerization and subsequent downstream signaling
events (Table 1) [90]. In hepatocellular carcinoma
(HCC), we observed that GALNT2 mRNA expression
exhibits significant down-regulation in HCC tissues
compared with normal counterparts. We also found that
GALNT2 expression suppresses cell malignant pheno-
types by modulating the O-glycosylation of EGFR, which
inhibits EGF-induced endocytosis and colocalization of
EGFR and its downstream signaling [91]. In oral
squamous cell carcinoma (OSCC), although GALNT2
expression can also modify the O-glycosylation of EGFR,
it can facilitate the activation and downstream signaling
of EGFR, thereby enhancing OSCC cell migration and
invasion (Table 1) [92].
Glycosyltransferases may serve as biomarkers for NB
From the series of studies above, it is postulated that
different cell types possess differential expression
patterns (repertoire) of isoenzymes, which may result in
different glycosylation sites or densities of cell-surface
receptors [93]. GALNT2, for example, may add GalNAc
to different O-glycosites on EGFR in HCC and OSCC
cells, which is determined by the repertoire of GALNTs
in respective cells. Therefore, EGFR glycoforms
modulated differentially by GALNT2 in these cells may
present with opposite cellular properties, including cell
proliferation, growth, oncogenesis, and metastasis.
Moreover, differential sialylation patterns of shorter
glycans (such as sTn, sLea/x, or di-sLea/x) regulated by
sialyltransferases are also attributed to specific glyco-
forms at the cell surface of these cancers.
Taken together, these enzymes could be potential candi-
dates for a panel of tumor markers for MRD detection or
treatment outcome of NB patients, yet the significance of
individual enzymes and more detailed molecular mecha-
nisms need further investigation. They will help to define
and develop personalized treatment for patients with NB.
Moreover, they may provide an alternative approach to
cancer therapy by means of modulating cancer-specific
glycosylation.
The roles of Gal-1 and CD44 in NB microenvironment
Soluble Gal-1 has been found to be secreted by different
NB cell lines and was identified as a major mediator of
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TrkB-mediated NB aggressiveness [6]. Additionally, NB-
derived Gal-1 may dampen the function of T cells and
dendritic cells [94]. Gal-1 may also mediate attachment
of cancer cells to the ECM and endothelial cells through
binding to CD44 (Fig. 3) [95].
CD44, a complex transmembrane glycoprotein, was
found to be closely associated with the development of
various solid tumors in terms of cancer stemness and
epithelial-mesenchymal transition (EMT) [60]. However,
CD44 is generally downregulated in human NB cells
[96]. Unlike other cancers, the absence of CD44 expres-
sion indicates aggressiveness and poor clinical outcome
in NB [97]. One of the CD44 isoforms, CD44v6,
contains sequences encoded by variant exon v6. CD44v6
serves as the carrier of T and sTn antigens in colon
cancer cells and has been linked to metastatic spreading
of a number of malignancies [60]. In NB, the induction
of CD44V isoform (especially CD44v6) expression by
12-O-tetradecanoyl phorbol-13-acetate (TPA), IGF-1,
and PDGF was correlated with an increased cellular
binding to hyaluronic acid (a major counterreceptor for
CD44; free form of GAGs in ECM) by phosphoinositide
3-kinase (PI3K)/protein kinase C (PKC) pathways,
indicating the impact of glycosylation status and local
distributions of the molecule on the changes in NB cell
properties (Fig. 3) [98]. The interactions between Gal-1,
CD44, and other associated molecules have made them
become interesting therapeutic targets and/or prognostic
factors for patients with NB.
Disialoganglioside expression and therapeutic
applications in NB
In normal human tissues, GD2 is a surface glycolipid
antigen expressed on neurons, skin melanocytes, and
peripheral sensory nerve fibers. In NB, GD2 (synthesized
by the GD2 synthase) is uniformly expressed by virtually
all neuroblasts and is involved in the attachment of NB
cells to ECM proteins (Fig. 3) [20]. This feature makes
GD2 potentially suitable for a molecular marker for
residual disease (but not a prognostic marker) and a
target for immunotherapy. Although the use of isotreti-
noin (13-cis-retinoid acid) has been incorporated into
the standard treatment as a biotherapy for high-risk NB
patients, monoclonal antibodies directed against NB-spe-
cific antigens such as GD2 may provide another
efficacious approach to eliminate residual NB cells by
complement-dependent cytotoxicity (CDC) and antibody-
dependent cell-mediated cytotoxicity (ADCC). There are
four major anti-GD2 monoclonal antibodies (mAbs) (3F8,
hu3F8, ch14.18, and hu14.18) being extensively tested in
clinical settings [12]. A phase III randomized study
reported by Yu et al. showed that adding immunotherapy
(ch14.18 in combination with granulocyte-macrophage
colony-stimulating factor (GM-CSF) and interleukin
(IL)-2 to enhance the ADCC) to isotretinoin therapy, as
compared with the use of isotretinoin alone, improved the
survival of children with high-risk NB in remission after
myeloablative therapy and stem-cell rescue [99]. A recent
study even suggests that autologous stem-cell transplant-
ation may not be needed to improve outcome when
anti-GD2 immunotherapy is used for consolidation after
dose-intensive conventional chemotherapy [100]. Further
clinical investigations of several novel combinatorial
immunotherapies are underway and will provide new
hope for infants and children with NB.
Conclusions
Glycan-based therapeutics in cancers
The presence of glycans on various biomolecules shows
their physiological and pathological importance; there-
fore, glycan-based therapeutics has been developed for
treatment of cancers and other diseases, such as glyco-
syltransferase inhibitors, glycomimetics, glycan/glyco-
peptide vaccines, antibody therapies, and antibody-based
immunotherapies. Sialic acid and fucose are the
common glycan structures on the terminal branches of
N- and O-glycans of glycoproteins and are involved in
cancer progression and metastasis. It has been reported
that the cell-permeable, fluorinated analogs of fucose
and sialic acid can be used as inhibitors of both fucosyl-
transferases and sialyltransferases and drastically re-
duced sLex expression on myeloid cells, resulting in loss
of binding to selectins and impaired leukocyte rolling
[101]. Several other inhibitors that target sialyltrans-
ferases have been developed, such as soyasaponin-I
(selectively inhibits α2,3-sialyltransferases activity) and
AL10 (inhibits α2,3- and α2,6-sialyltransferases activity),
for treatment of metastatic breast and lung cancer cells,
respectively [13, 14]. Glycomimetic drugs such as acety-
lated or/and fluorinated derivatives of glycans (4F-Gal-
NAc and 4F-GlcNAc) were used as decoys to disrupt the
biosynthesis of natural ligands for selectins, which
blocked selectin interaction with the endogenous glycans
and mediated cellular adhesion [102]. These studies may
pave the way for the broader use of these glycosyltrans-
ferase inhibitors or glycomimetics in NB patients.
However, because all members of a given family utilize
the same donor substrate (such as GlcNAc for B3GNT3,
GalNAc for B4GALNT3 or GALNTs), the differential
cellular expression pattern and acceptor specificity of
each enzyme in NB cells need to be clarified further in
the future..
Unusual glycomotifs on glycoproteins can be recog-
nized by the immune system, but they are weak immu-
nogens. Therefore, vaccines of this type are typically
prepared by conjugating the glycan to a carrier protein
to boost both humoral and cellular immune responses,
such as the use of sTn-KLH vaccines in phase III clinical
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trials for breast cancer patients with metastatic disease
[103]. Other glycan/glycopeptide vaccines have been
designed and generated to elicit more robust immune
responses, such as the development of synthetic vaccines
consisting of a MUC1 glycopeptide along with a T
helper (Th) peptide [104], a MUC1 glycopeptide along
with toll-like receptor 2 (TLR2) lipopeptide ligands [105]
or a MUC1 glycopeptide along with a Th peptide and a
TLR2/TLR9 agonist [106]. Multivalent vaccines targeting
multiple mucins have been developing against various
cancers [22]. To date, advances in availability of
recombinant glycosyltransferases have made it possible
to synthesize cancer-associated antigens mimicking the
surface of cancer cells in terms of glycosylation sites and
density, which allows for specific targeting cancer cells
with immunotherapeutics [22].
NB-associated glycoforms provide information with
which cancer vaccines are designed and synthesized. For
example, a phase I trial of a bivalent GD2-GD3 ganglio-
sides vaccine in combination with the immunostimulant
β-glucan revealed an encouraging result in high-risk NB
patients [107]. Another vaccine target used for NB is N-
glycolyl GM3 (NeuGcGM3), which is expressed in 85 %
of NB cases, including those with MYCN amplification
[108]. Racotumomab is a murine anti-idiotype vaccine
that mimics NeuGcGM3 and was reported to trigger an
anti-NeuGcGM3 response in adults with melanomas
[15], lung cancers [16], and breast cancers [17]. A phase
I study using racotumomab in children with NB and
other refractory malignancies revealed that most patients
elicited an immune response against racotumomab but
did not show significant anti-tumor activity in most
cohort patients who were heavily pre-treated with
front-line therapy. Therefore, evaluation of long-term
vaccination with this vaccine is underway [109].
Perspectives on glycosylation-based therapies for NB
It is well-known that receptor kinases that mediate arrest
and differentiation tend to have low multiplicity, and their
dependency on N-glycan branching or O-glycosylation for
surface residency is altered by oncogenesis-driven
membrane remodeling. We reason that “nontransformed”
dynamics can be restored by jointly manipulating protein
synthesis, N- or O-glycosylation, and Golgi remodeling to
change the cell-surface glycosylation pattern involved in
growth and arrest [34]. Moreover, epigenetic mechanisms
on glycogenes (e.g., DNA methylation, histone modifica-
tions, and non-coding RNAs [110–117]) (Table 2) associ-
ated with cell-surface glycosylation in various cancers may
develop as potential targets for anti-tumor therapy in the
near future.
So far, almost all approved mAbs are targeting protein
antigens, except anti-GD2 mAbs. Anti-GD2 antibodies
have been actively tested since 1980s in various
preclinical and clinical combinatorial trials for NB, and
now have proved their safety and efficacy when
combined with GM-CSF and IL-2 in the treatment of
high-risk NB patients. An interesting fusion protein,
namely hu14.18-IL2, has been generated by fusing an
IL-2 moiety to hu14.18 mAb. This fusion protein has
shown superior anti-tumor activity as compared with
ch14.18 mAb combined with IL-2 in NB patients with
nonbulky disease [118]. Building on the success of
ch14.18, researchers are using T cells, engineered to
express a new class of proteins known as chimeric anti-
gen receptors (CARs), to enhance anti-tumor efficacy.
Therefore, engineered human T lymphocytes expressing
GD2-directed CARs (GD2-CARs) were generated. Louis
et al. found that these GD2-CAR T cells can induce
complete tumor responses in patients with active NB
and have extended, low-level persistence associated with
longer survival outcome in these patients [119].
Many approaches have been developed to improve the
efficacy of therapeutic antibodies; Potelligent® Technology
is one of the most potent technologies for enhancing
ADCC [120]. The concept of this technology originated
from the discovery that reducing or eliminating fucose
from the oligosaccharides on the Fc domain significantly
increased FcγRIIIa binding and dramatically enhanced
ADCC by ~100-fold [121]. In addition, an antibody
without fucose is a natural component of human serum
and therefore has a lower risk of immunogenicity. A
defucosylated anti-CC chemokine receptor 4 (CCR4),
mogamulizumab, not only induces ADCC against CCR4+
malignant T cells but also reduces CCR4+ regulatory T
cells (Tregs) which in turn restores NK cell anti-tumor
function in patients with cutaneous T cell lymphoma
(CTCL) [18]. This drug was approved in Japan for CCR4-
positive adult T cell leukemia/lymphoma (ATL) in 2012
[19], relapse/refractory CCR4-positive peripheral T cell
lymphoma (PTCL) and CTCL in 2014. Another form of
defucosylated antibody, nivolumab, is a programmed
death-1 (PD-1) immune-checkpoint inhibitor. PD-1 is a
key immune-checkpoint receptor expressed by activated
T cells and mediates immunosuppression. Blockade of the
interaction between PD-1 (on activated T cells) and
PD-L1 (PD-1 ligands; expressed on tumor cells or stromal
cells) can enhance T cell activity and anti-tumor activity
[122]. Nivolumab is approved to be used alone or with
other drugs to treat metastatic melanoma, non-small cell
lung cancer, and renal cell carcinoma. Anti-GD2 mAb in
combination with anti-PD-1 mAb has been added to the
present treatment protocols for high-risk NB and is likely
to be studied in the future [123, 124]. The mutated hu-
manized antibody, hu14.18K322A (lysine to alanine in the
CH2 region critical for complement activation) produced
by YB2/0 cells, showed decreased fucosylation activity and
demonstrated increased ADCC and less complement
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activation (which was related to hypersensitivity reactions)
than ch14.18. Therefore, this antibody has the potential to
be less toxic, allowing for higher maximum tolerated dose
(MTD) and improved efficacy for refractory/recurrent NB
patients [125].
Where do we go from here?
Recent advances in cancer cell glycomics have expanded
the armamentarium of NB therapeutic targets. However,
treatment of high-risk NB is still challenging because
~40 % of patients still relapse during or after glycan-based
immunotherapy following standard therapy [99]. In the last
two decades, several anti-GD2 antibodies and GD2-GD3
vaccines have been developed and tested in clinical trials,
resulting in various treatment responses. Development of
an immune response is always a concern with genetically
engineered mAbs, such as human anti-mouse antibodies
(HAMA), human anti-human antibodies (HAHA), or
anti-chimeric-antibodies, which may influence the level of
antibody therapy and potentially contribute to the undesir-
able adverse effects [126, 127]. Maintaining anti-tumor
antibodies over months or years is more readily achievable
with vaccines than with mAbs. However, Kushner et al.
postulated that fluctuations in anti-GD2 titers in vaccinated
patients may represent multiple idiotypes within an
idiotypic network [107]. Nevertheless, these results support
the idea of using GD2-GD3 vaccine as an adjuvant therapy
in patients with low disease burdens but at high risk for
relapse and with target antigens highly expressed in
cancerous tissues but not normal tissues, after these
patients have completed the standard upfront multimodal
treatments [107].
In conclusion, aberrant protein glycosylation in tumor
cells and NB microenvironment provides clinicians with
additional opportunities to screen for specific glycosyl-
transferase inhibitors, glycomimetics, and glycan-based
vaccines/immunotherapies. This feature also allows the
development of novel genetically and epigenetically
based therapies. Further investigation of the intricate
glycoforms on NB cells may lead to the identification of
more useful prognostic, diagnostic, and therapeutic
targets in the future.
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Table 2 Identified glycogene/miRNA interactions in human diseases
miRNAs Glycogene targets Comments
miR-30b/30d GALNT1, GALNT7 Both GALNT1 and GALNT7 are targets of miR-30b/d, which are associated
with metastasis in melanoma [112].
miR-378 GALNT7 GALNT7 is a target of miR-378 and plays a critical role in osteoblast
differentiation [111].
miR-122 GALNT10, FUT8 GALNT10 modulates O-glycosylation of EGFR in hepatitis B virus (HBV)-infected
hepatoma cells. GALNT10 is a target of miR-122, whose gene transcription is
activated by hepatocyte nuclear factor 4α (Hnf4α). Therefore, a regulatory pathway
of Hnf4α/miR-122/GALNT10/EGFR may develop as therapeutic targets [113].
Ectopic expression of miR-122 can significantly decrease FUT8 levels, thus may play
a role in the dysregulation of core fucosylation observed in liver tumors [114].
miR-27a B4GALT3 B4GALT3 up-regulated by miR-27a contributes to the tumorigenic activities by
β1-integrin pathway and might provide potential biomarkers for cervical cancer [117].
miR-148b C1GALT1 Inhibition of miR-148b expression can reverse the lower levels of C1GALT1 typical
of IgA nephropathy. Therefore, miR-148b levels may be manipulated to provide a
therapeutic approach to the disease [110].
miR-199b-5p FUT4 The cluster of differentiation carbohydrate antigen CD15, also known as FUT4, is a
marker of medulloblastoma tumor-propagating cells and an additional direct target
of miR-199b-5p. Therefore, the finely tuned regulation of miR-199b-5p may have a
role in therapeutic application in medulloblastoma [115].
miR-34a FUT8 Ectopic expression of miR-34a can significantly decrease FUT8 levels, thus may play
a role in the dysregulation of core fucosylation observed in liver tumors [114].
miR-125b ERManI ERManI functions as a “gate keeper” in the Golgi complex to facilitate the retention
and recycling of misfolded glycoproteins escaped from the ER. In hepatoma cells,
however, ERManI regulates transformation phenotypes independent of ER-stress.
ERManI knockdown by miR-125b inhibits proliferation and migration of hepatoma
cells [116].
B4GALT3 β1,4-galactosyltransferase 3, C1GALT1 core 1 β1,3-galactosyltransferase, FUT fucosyltransferase, GALNT N-acetylgalactosaminyltransferase, ERManI human
endoplasmic reticulum alpha-1, 2-mannosidase I
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